Although comparative efficacy of palonosetron in multiple cycles has not been demonstrated in controlled clinical trials, 875 patients enrolled in the three phase 3 trials continued in an open label safety study and were treated with palonosetron 750 micrograms for up to 9 additional cycles of chemotherapy.